Company Overview and News
KUALA LUMPUR (July 16): The FBM KLCI edged up in early trade this morning but gains were seen limited in line with the slower start at most regional markets.
TGLVY SPMXY 3867 SPMXF UPBMF 7113 TPGVF 2836 7022 2089 GBTKF
KUALA LUMPUR (July 13): The FBM KLCI rose 0.74% at midday break today, tracking gains at most regional markets, lifted by factors including key heavyweight index-linked stocks.
7052 UPBMF 5681 9679 2089 CIMDF 1023 3204 4863 5347 3867 0026 TNABY 6888 4723 AXXTF MYTEF TNABF GEBHF
KUALA LUMPUR (July 13): The FBM KLCI pared some of its gains at mid-morning but remained firmly above the crucial 1,700-point level, tracking the advance at regional markets.
HLFBF 5183 BRDBF SPMXF PECGF UPBMF 1082 5681 9679 BATS 4162 7153 2089 5210 3204 SPMXY 3301 3867 0026 2739
KUALA LUMPUR, July 12 — Bursa Malaysia extended gains for a fourth consecutive day with the benchmark index closing at a near three-week high today, bolstered by positive regional sentiment and strong gains in index-linked counters led by Maybank.
HLFBF 3204 PBLOF 5225 3867 5819 1082 1295 Q0F BSMAF IHHHF 1818
KUALA LUMPUR (July 12): The FBM KLCI reversed its earlier losses and climbed 0.44% at midday break, tracking regional markets, lifted by gains including at banking heavyweights Malayan Banking Bhd and Pulic Bank Bhd.
PBLOF MLYBY SPMXF MLYNF BATS 4162 1295 7153 5168 1155 KLKBY 3204 2445 SPMXY 4456 3301 3867 7205 0026 1899 5819 HRGHY
KUALA LUMPUR (July 12): The FBM KLCI remained presured at mid-morning today, tracking regional markets as market sentiment stayed tepid with the spectre of a U.S.-China trade war still hanging over global markets.
HLFBF 7073 PBLOF 7113 4065 BATS TPGVF 4162 1295 7153 2089 KLKBY 3867 6139 7668 HRGHY UPBMF 1082 5168 0131 TGLVY 5139 2445 5216 0026 0900 1899 5819
KUALA LUMPUR (July 12): The FBM KLCI halted its ascend in ear;y trade this morning as regional markets stayed under pressure with escalating worries over the U.S.-China trade war.
HLFBF TGLVY 4588 3301 3867 5819 1082 7113 TPGVF BATS 4162 GEBHF
KUALA LUMPUR (July 4): The FBM KLCI rose at midday break today, lifted by gains at select index-linked blue chips, including Telekom Malaysia Bhd and Axiata Group Bhd, against the backdrop of weaker regional markets.
HLFBF 7084 1082 5031 BATS 4162 1163 0023 KLKBY 2445 4588 4863 5347 3867 0037 0026 TNABY 6888 5819 AXXTF MYTEF TNABF 3719
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719
KUALA LUMPUR (July 3): The FBM KLCI looked set to extend its losses today in line with the turbulent regional markets, as it fell 0.43% at the midday break.
HLFBF 5270 UPBMF 8621 7036 1082 4197 5681 BATS 4162 1163 2089 5199 KLKBY 2445 5347 3867 SMEBF TNABY TNABF HIPEF 3719
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF
12h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...